BioCentury
ARTICLE | Clinical News

GS-5745: Development discontinued

December 9, 2016 8:23 PM UTC

Gilead discontinued development of subcutaneous GS-5745 to treat CD and UC. The company said GS-5745 showed "no evidence of benefit" in a double-blind, placebo-controlled, international Phase II trial in patients with moderate to severe CD. Patients received 150 mg GS-5745 weekly or every 2 weeks and 300 mg GS-5745 weekly for 8 weeks. Earlier this year, Gilead discontinued a double-blind, placebo-controlled, international Phase II/III trial evaluating 2 dosing regimens of 150 mg GS-5745 in patients with moderate to severe UC. The company said there was “insufficient evidence of a treatment benefit” with either dosing regimen (see BioCentury, Sept. 26)...